Case report of hepatic toxicity and cognitive decline in a patient with advanced ALK-positive lung cancer, highlighting possible adverse events.
Alectinib is suggested as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Nevertheless, despite being generally well-tolerated, drug-related adverse events (AEs) like hepatotoxicity and cognitive impairment are still not fully understood. We report the case of a patient affected by stage IV ALK-positive NSCLC who developed hepatic toxicity and cognitive decline during Alectinib treatment.
No takes yet. Share an insight, caveat, or question.
Beatrice Ruffilli (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: